

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Lee Yatomi-Clarke
Date of last notice	11 October 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Arrow Wealth Ltd <Berbay Family A/C> (a controlled entity of Mr Yatomi-Clarke) Novetera Pty Ltd <SAYC Super Fund A/C> (a controlled entity of Mr Yatomi-Clarke) Alexandra Elizabeth Yatomi-Clarke
Date of change	14 December 2022

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	Direct 4,000,000 Fully paid ordinary shares 2,000,000 Unlisted Options exercisable at \$0.1016 (10.16 cents) per option, expiring 18 December 2022 3,500,000 Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023 Indirect <u>Arrow Wealth Ltd</u> 3,245,000 Fully paid ordinary shares <u>Novetera Pty Ltd</u> 1,889,178 Fully paid ordinary shares 97,692 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023 12,900,000 Unlisted Options, exercisable at \$0.0968 (9.68 cents) per option, expiring on 23 November 2024 <u>Alexandra Elizabeth Yatomi-Clarke</u> 172,500 Fully paid ordinary shares
Class	Fully Paid Ordinary Shares
Number acquired	641,711 Fully Paid Ordinary Shares
Number disposed	2,000,000 Unlisted Options exercisable at \$0.1016 (10.16 cents) per option, expiring 18 December 2022 (cancelled upon exercise)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A (exercise of employee options)
No. of securities held after change	Direct 4,641,711 Fully paid ordinary shares 3,500,000 Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023 Indirect <u>Arrow Wealth Ltd</u> 3,245,000 Fully paid ordinary shares <u>Novetera Pty Ltd</u> 1,889,178 Fully paid ordinary shares 97,692 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023 12,900,000 Unlisted Options, exercisable at \$0.0968 (9.68 cents) per option, expiring on 23 November 2024 <u>Alexandra Elizabeth Yatomi-Clarke</u> 172,500 Fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares upon the exercise of employee options utilising a cashless exercise facility
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.